https://www.selleckchem.com/pr....oducts/napabucasin.h
98). Adjuvant chemotherapy was given in 15% of patients in the VL and 11% in the VS group. During follow-up (median 23 months), no patients presented with local nodal recurrence or on the stapler line (VS group). Three patients on VL and two in VS groups presented with recurrence on the remnant operated lung. New primary pulmonary tumors were diagnosed in 3.3% and 6.3% of patients in the VL and VS groups, respectively. Despite the short follow-up, our preliminary data shows that local control is comparable for VATS lobectomy and VAT
Aimer
Commentaire
Partagez
